Investigation of Aptinyx Inc.

Aptinyx Inc. (APTX)'s Drug Fails to Meet Primary Endpoint

On January 16, 2019, Aptinyx announced that its drug, NYX-2925, did not achieve statistically significant separation from the placebo on a primary end point in its phase 2 trial. On this news, shares of Aptinyx fell $11.85, or 67%, to close at $5.98. The stock has yet to recover and currently trades at around $3.50, a 78% decline from its IPO price.

Send us a message for more information.

Additional Alerts for Shareholders

chalkboard with INVESTIGATION handwritten in chalk

RxSight, Inc. Class Action

Robbins LLP Informs RxSight, Inc. Stockholders that it is Investigating the Officers and Directors of RXST to Determine if They Breached Fiduciary Duties Owed to Shareholders

Read More »
Free!
Skip to content